MX2024007731A - Formulaciones del factor i del complemento. - Google Patents
Formulaciones del factor i del complemento.Info
- Publication number
- MX2024007731A MX2024007731A MX2024007731A MX2024007731A MX2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- cfi
- complement factor
- wild
- variants
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000003689 Complement Factor I Human genes 0.000 title 1
- 108090000044 Complement Factor I Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21045—Complement factor I (3.4.21.45)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293013P | 2021-12-22 | 2021-12-22 | |
| PCT/US2022/082179 WO2023122691A1 (en) | 2021-12-22 | 2022-12-21 | Complement factor-i formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007731A true MX2024007731A (es) | 2024-07-01 |
Family
ID=85172701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007731A MX2024007731A (es) | 2021-12-22 | 2022-12-21 | Formulaciones del factor i del complemento. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250009855A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4452321A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025503483A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240124950A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118450906A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022420007A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241714A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313777A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024007731A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023122691A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| US20220347265A1 (en) * | 2019-10-23 | 2022-11-03 | Gemini Therapeutics Sub, Inc. | Methods for treating patients having cfi mutations with recombinant cfi proteins |
| WO2021257480A2 (en) * | 2020-06-14 | 2021-12-23 | Catalyst Biosciences, Inc. | Complement factor i-related compositions and methods |
-
2022
- 2022-12-21 CA CA3241714A patent/CA3241714A1/en active Pending
- 2022-12-21 MX MX2024007731A patent/MX2024007731A/es unknown
- 2022-12-21 IL IL313777A patent/IL313777A/en unknown
- 2022-12-21 KR KR1020247022975A patent/KR20240124950A/ko active Pending
- 2022-12-21 JP JP2024537890A patent/JP2025503483A/ja active Pending
- 2022-12-21 AU AU2022420007A patent/AU2022420007A1/en active Pending
- 2022-12-21 EP EP22854364.1A patent/EP4452321A1/en active Pending
- 2022-12-21 CN CN202280084962.2A patent/CN118450906A/zh active Pending
- 2022-12-21 WO PCT/US2022/082179 patent/WO2023122691A1/en not_active Ceased
-
2024
- 2024-06-21 US US18/750,927 patent/US20250009855A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4452321A1 (en) | 2024-10-30 |
| CN118450906A (zh) | 2024-08-06 |
| US20250009855A1 (en) | 2025-01-09 |
| IL313777A (en) | 2024-08-01 |
| KR20240124950A (ko) | 2024-08-19 |
| AU2022420007A1 (en) | 2024-06-20 |
| CA3241714A1 (en) | 2023-06-29 |
| WO2023122691A1 (en) | 2023-06-29 |
| JP2025503483A (ja) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Challenges in delivering therapeutic peptides and proteins: A silk-based solution | |
| Leong et al. | Amoeboid and ramified microglia: their interrelationship and response to brain injury | |
| CO2021013878A2 (es) | Vectores de virus adenoasociado recombinantes | |
| CL2021001957A1 (es) | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración. (divisional solicitud 202002872) | |
| ES2037094T3 (es) | Cateter de balon multiple para angioplastia. | |
| ES2083876T3 (es) | Cateter para inyectar medicamentos. | |
| AR036065A2 (es) | Un metodo para suministrar una droga en el ojo humano | |
| ES2092702T3 (es) | Cateter con balon separable para tratamiento endoscopico. | |
| DE602006016058D1 (de) | Vorrichtungen zur Behandlung von empfänglicher Plaque | |
| ATE465255T1 (de) | Verabreichung von sirnas | |
| DE60139194D1 (de) | Nasentamponade | |
| Myung et al. | Platelet‐rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model | |
| ES2182899T3 (es) | Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii. | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| Wiggins-Dohlvik et al. | Melatonin inhibits thermal injury–induced hyperpermeability in microvascular endothelial cells | |
| ES2093122T3 (es) | Activacion mejorada de proteinas recombinantes. | |
| AR122066A1 (es) | Injerto de stent | |
| ES2527664T3 (es) | Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina | |
| AR110031A1 (es) | Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa | |
| AR128464A1 (es) | Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada | |
| Yam et al. | Axonal injury caused by focal cerebral ischemia in the rat | |
| McCully et al. | Letter by McCully et al Regarding Article,“Mitochondria do not survive calcium overload | |
| ES2119165T3 (es) | Nueva actividad de cofactor anticoagulante. | |
| Ho et al. | Immunomodulation With Local, Sustained Delivery of Pituitary Adenylate Cyclase Activating Polypeptide Results in Improved Functional Recovery in Stroke‐Injured Mice | |
| CN105999527A (zh) | 鼻腔给药装置 |